MedTrace Logo

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

NCT03266601 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 668

Last updated 2019-03-07

No results posted yet for this study

Summary

This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.

Conditions

  • Herpangina

Interventions

DRUG

Recombinant Human Interferon α-2b Spray

Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).

DRUG

Ribavirin

Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).

Sponsors & Collaborators

  • Tianjin Sinobioway Biomedicine Co.Ltd.

    collaborator UNKNOWN

  • Hunan Children's Hospital

    collaborator OTHER_GOV

  • Children's Hospital of Chongqing Medical University

    collaborator OTHER

  • Yuying Children's Hospital of Wenzhou Medical University

    collaborator OTHER

  • Qilu Children's Hospital of Shandong University

    collaborator OTHER

  • Children's Hospital of Kaifeng City

    collaborator UNKNOWN

  • Shenzhen Children's Hospital

    collaborator OTHER_GOV

  • Zunyi Medical College

    collaborator OTHER

  • Changhai Hospital

    collaborator OTHER

  • Anhui Provincial Children's Hospital

    collaborator OTHER

  • Children's Hospital of Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266601 on ClinicalTrials.gov